For an emerging life sciences company, the most valuable aspect of the business may not always be in the lab. It could be the clinical data generated over years of research, the proprietary algorithms, experimental processes or the regulatory submission that could determine whether a product ever reaches the market.
Increasingly, these assets exist entirely digitally and that can change the cyber risk equation. A cyber incident can mean far more than ransom demands or the cost of replacing compromised hardware. For a business working towards a clinical milestone, funding round or regulatory approval, disruption itself can have serious consequences.
The question for life sciences businesses is becoming less about whether they can prevent every cyber incident and more about whether they are resilient enough to keep moving then one strikes.
Small Company, Significant Exposure
Emerging biotech and life science companies can look relatively small from the outside. For example, they may have limited teams and internal infrastructure and a heavy reliance on outsourced expertise. But their digital assets can be significant.
Research data can take years and cost millions to generate. Clinical trial datasets cannot simply be recreated. Manufacturing processes, biological research and AI models may underpin a company's entire future valuation. That makes life sciences businesses attractive targets, regardless of how many people they employ.
The consequences of an attack may not be immediately visible. The loss of intellectual property today could affect competitive advantage years down the line, while disruption to a clinical programme could create much more immediate commercial and operation pressure.
Is Your Cyber Perimeter Your Own?
Another factor that makes life sciences particularly interesting from a cyber perspective is that very little happens by itself. CROs, CDMOs, specialist laboratories, bioinformatics providers, cloud platforms, consultants and other partners can all play a critical role in bringing a therapy from research to reality. They may also have access to the information that makes that therapy valuable.
As companies grow, so does this network. More suppliers, more systems, more data exchanges and more people with access create a broader ecosystem to manage. That means cyber resilience cannot stop at the company’s own network. Understanding where critical information sits, who can access it and how those third parties protect it needs to become part of the wider manager conversation.
Growth Creates a Different Kind of Cyber Risk
For many emerging life sciences companies, growth is fast - clinical programmes expand, teams grow, international collaborations become routine and new supplier and technology platforms are introduced.
The operational infrastructure can become more complicated long before the internal capability to manage it catches up. This is where cyber resilience becomes a growth issue rather than an IT problem.
Investors are increasingly looking beyond the science and financials to understand how well a company manages the operations risks around them, asking questions like:
Where is sensitive research stored?
Which suppliers have access to it?
What happens if a critical third party suffers an incident?
How quickly could operations recover?
Could a cyber event delay key development milestones?
These questions can reveal a great deal about how prepared a business is for its next stage of growth.
Resilience Means Knowing What Matters Most
No organisation can eliminate cyber risk completely. For life sciences companies, the starting point should be understanding what would matter most if something went wrong. That means identifying critical information and the systems and suppliers that support it, then considering how those dependencies are protected.
Cyber maturity should sit alongside scientific capability, quality systems and commercial performance when assessing suppliers. When timelines are tight and clinical or commercial milestones are on the line, these measures become critical:
Set clear expectations from the outset with contracts that define data security requirements and incident notification procedures.
Maintain ongoing supplier oversight to identify vulnerabilities before they escalate into business-critical issues.
Prepare people as well as systems through staff training and regularly tested response plans, enabling organisations to react quickly when technology fails or access is compromised.
Insurance As Part of the Resilience Conversation
Cyber insurance has also moved beyond being viewed purely as a financial backup plan. For life sciences businesses, the value of a policy can lie as much in the response as the indemnity.
Specialist forensic investigators, legal advisors, breach coaches, crisis communications experts and technical recovery teams can all play a role in helping a company understand what has happened, contain the incident and restore operations.
That is important when the impact of an incident extends beyond the balance sheet. A ransomware event is one thing - an incident that delays a clinical trial, compromises proprietary research or takes a critical supplier offline can trigger a very different set of consequences.
For that reason, life sciences businesses need to look closely at how a cyber policy responds to their particular operating model, including incidents involving third-party suppliers and the specialist support available when something goes wrong.
Protect the Science, Protect the Infrastructure
The life sciences company that succeeds will need to demonstrate that they can protect the information, relationships and operational infrastructure supporting it.
Cyber resilience is therefore becoming part of the foundations of growth. For a company working towards tomorrow’s therapy, protecting today’s information is part of protecting the research, investment and development that could ultimately get that therapy into the hands of patients who need it.
